ACIU Estados financieros: Análisis de AC Immune SA AI

Inicio

Acciones

ACIU

ACIU Financiero

AC Immune SA

$2.99

2.04%

$0.06

Al cierre: Feb 13, 16:00:00 GMT-5

$2.99

Mercado Posterior: Feb 13, 20:00:00 GMT-5

Visión general Pronóstico Ganando Dividendos Finanzas

Ingreso

Balance general

Flujo de efectivo

Anual

Trimestral

ACIU Ingreso

Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Ingresos	4	27	14	3	0	15
Crecimiento de los Ingresos (YoY)	-90%	93%	367%	--	-100%	-86%
Costo de los ingresos	--	--	--	--	--	--
Utilidad bruta	--	--	--	--	--	--
Venta, General y Administración	11	11	10	9	10	11
Investigación y Desarrollo	61	62	54	60	62	59
Gastos de Operación	77	79	68	74	79	76
Otras Ingresos (Gastos) No Operativos	--	--	--	--	0	0
Ingreso antes de impuestos	-71	-50	-54	-70	-73	-61
Gasto por Impuesto a la Renta	0	0	0	0	0	0
Ingreso Neto	-71	-50	-54	-70	-73	-61
Crecimiento de la Utilidad Neta	82%	-7%	-23%	-4%	20%	-236%
Acciones en Circulación (Diluidas)	100.89	99.69	84.69	83.6	75	71.9
Cambio de Acciones (YoY)	0%	18%	1%	11%	4%	1%
EPS (Diluido)	-0.71	-0.51	-0.64	-0.85	-0.97	-0.86
Crecimiento de EPS	75%	-20%	-25%	-12%	13%	-234%
Flujo de efectivo libre	-47	65	-61	-74	-68	-61
Flujo de efectivo libre por acción	--	--	--	--	--	--
Margen bruto	--	--	--	--	--	--
Margen de operación	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
Margen de beneficio	-1,775%	-185.18%	-385.71%	-2,333.33%	0%	-406.66%
Margen de flujo de caja libre	-1,175%	240.74%	-435.71%	-2,466.66%	0%	-406.66%
EBITDA	-71	-50	-51	-68	-77	-60
Margen de EBITDA	-1,775%	-185.18%	-364.28%	-2,266.66%	0%	-400%
D&A para EBITDA	2	2	2	2	2	1
EBIT	-73	-52	-53	-70	-79	-61
Margen de EBIT	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
Tasa de Impuesto Efectiva	0%	0%	0%	0%	0%	0%

Estadísticas clave

Cierre Anterior

$2.93

Precio de apertura

$2.97

Rango del día

$2.93 - $3.03

Rango de 52 semanas

$1.42 - $4

Volumen

145.8K

Volumen promedio

593.7K

EPS (TTM)

-0.72

Rendimiento de dividendos

Cap. de mercado

$300.2M

¿Qué es ACIU?

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.



Características

Copiloto de IA para Acciones y Criptomonedas

Predicción de precios

Seguimiento de Recaudación de Fondos

Temas

Comparación de Criptomonedas

Recursos